| Wissenschaftl. Titel | A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011) |
| Erkrankung |
Niere/Harnwege:
Harnblasenkrebs:
Erstlinie
|
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
erstellt 22.05.2020 Student Studienregister
geändert 07.10.2022 Student Studienregister